via European Pharmaceutical Review
Inserting genetic material into the body to treat diseases caused by gene mutations can work, scientists say – but getting those materials to the right place safely is tricky.
Scientists report today (Aug. 21) in the journal Science Advances that the lipid-based nanoparticles they engineered, carrying two sets of protein-making instructions, showed in animal studies that they have the potential to function as therapies for two genetic disorders.
In one experiment, the payload-containing nanoparticles prompted the production of the missing clotting protein in mice that are models for hemophilia. In another test, the nanoparticles’ cargo reduced the activation level of a gene that, when overactive, interferes with clearance of cholesterol from the bloodstream.
Each nanoparticle contained an applicable messenger RNA – molecules that translate genetic information into functional proteins.
“We demonstrated two applications for lipid-like nanomaterials that effectively deliver their cargo, appropriately biodegrade and are well-tolerated,” said Yizhou Dong, senior author of the study and associate professor of pharmaceutics and pharmacology at The Ohio State University.
“With this work, we have lowered potential side effects and toxicity, and have broadened the therapeutic window. This gives us confidence to pursue studies in larger animal models and future clinical trials.”
This work builds upon a collection of lipid-like spherical compounds that Dong and colleagues had previously developed to deliver messenger RNA. This line of particles was designed to target disorders involving genes that are expressed in the liver.
The team experimented with various structural changes to those particles, effectively adding “tails” of different types of molecules to them, before landing on the structure that made the materials the most stable. The tiny compounds have a big job to do: embarking on a journey through the bloodstream, carrying molecules to the target location, releasing the ideal concentration of messenger RNA cargo at precisely the right time and safely degrading.
The tests in mice suggested these particles could do just that.
The researchers injected nanoparticles containing messenger RNA holding the instructions to produce a protein called human factor VIII into the bloodstream of normal mice and mouse models for hemophilia. A deficiency of this protein, which enables blood to clot, causes the bleeding disorder. Within 12 hours, the deficient mice produced enough human factor VIII to reach 90 percent of normal activity. A check of the organs of both protein-deficient mice and normal mice showed that the treatment caused no organ damage.
“It can be helpful to think of this as a protein-replacement therapy,” Dong said.
In the second experiment, nanomaterials were loaded with two types of instructions: messenger RNA carrying the genetic code for a DNA base editor, and a guide RNA to make sure the edits occurred in a specific gene in the liver called PCSK9. Dozens of mutations that increase this gene’s activity are known to cause high cholesterol by reducing clearance of cholesterol from the bloodstream.
Analyses showed that the treatment resulted in the intended mutation of about 60 percent of the target base pairs in the PCSK9 gene, and determined that only a low dose was needed to produce high editing effect.
Dong credited academic and industry partners for helping advance this work. Co-corresponding authors include Denise Sabatino of Children’s Hospital of Philadelphia and Delai Chen from Boston-based Beam Therapeutics, who provided expertise in hemophilia and DNA base editing, respectively.
Dong and first author Xinfu Zhang are inventors on patent applications filed by Ohio State related to the lipid-like nanoparticles. This technology has been licensed for further clinical development.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Taysha Gene Therapies Announces New Data on Multiple Preclinical Programs and Upcoming R&D Dayon April 14, 2021 at 4:00 am
TSHA-113 significantly reduced tau mRNA and protein levels in mouse models of human ... portfolio and we are encouraged by the results of our gene therapy approach of vectorized RNA and gene ...
- Cincinnati startup gets key FDA approval for potential Covid-19 therapyon April 12, 2021 at 11:10 am
Sharonville’s Airway Therapeutics said Monday the FDA accepted the company's investigational new drug application to also develop its protein replacement therapy, known as AT-100, as a treatment for ...
- Metabolism Drugs Market Size Is Estimated to Witness a CAGR of 6.3% By 2026, Finds Coherent Market Insightson April 8, 2021 at 7:30 am
Metabolism involves breaking down of carbohydrates, proteins, and fats present in the consumed food, to generate energy. It also includes the excretion of nitrogen through urine, and breaking down or ...
- New Genentech Data at 2021 AAN Highlight Impact and Breadth of Expanding Neuroscience Portfolioon April 7, 2021 at 10:01 pm
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data for its approved and investigational medicines for the treatment of neurological disorders will be ...
- Pharming Group announces the filing of its 2020 Annual Report on Form 20-F with the U.S. Securities and Exchange Commissionon April 7, 2021 at 1:00 pm
Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces the filing of its Annual Report on Form 20-F for the year ended 31 December 2020 with the U.S.
Go deeper with Google Headlines on:
Go deeper with Bing News on:
Engineered therapeutic delivery system
- Engineering the Future of Genetic Medicineon March 31, 2021 at 7:54 am
This will be achieved through its "CRISPR by Design" platform that can engineer novel molecules designed for in vivo therapeutic use ... of genetic medicine such as delivery into the human body. We ...
- Red Blood Cells Engineered to Deliver More Than Oxygenon March 30, 2021 at 5:00 pm
The result of the team's work, "Engineered Red Blood Cells as Carriers for Systemic Delivery of a Wide Array of Functional ... that can express what we want and potentially be used for therapeutic or ...
- A New Approach To Crispr - Scribe Therapeutics Designs Novel Crispr Moleculeson March 30, 2021 at 5:00 pm
AAV vectors can deliver DNA to specific target cells for therapeutic uses ... to be better and more effective for delivery in many different organ systems and will reach more than what people ...
- Scientists develop new platelet-based formulation for combination anticancer therapyon March 26, 2021 at 11:01 am
Researchers from the Institute of Process Engineering (IPE ... a new platelet-based formulation which demonstrated potent therapeutic effects against cancer in murine models.
- Building new roads to stronger immunityon March 24, 2021 at 12:35 pm
1 Department of Chemical and Biomolecular Engineering ... which have the potential to train the immune system to eradicate tumors and prevent disease recurrence. Though the clinical success of ...